undamentalytics Newsletter
Sign in

Century Therapeutics, Inc. revenue

Century Therapeutics, Inc.'s revenue was $109m in fiscal 2025, up 1556.8% on the year before. Since fiscal 2022 ($5.2m) it has grown at a compound 175.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue527109
Growth on the year before—−57.0%+194.8%+>999%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Century Therapeutics, Inc. $109m 1556.5% 175.9%
Xencor Inc $105m -28.6% -2.5%
Kymera Therapeutics, Inc. $102m 133.8% 29.7%
ARS Pharmaceuticals, Inc. $117m 4.1% 711.3%
Arcus Biosciences, Inc. $117m -55.3% -1.1%
Mesoblast LTD $120m 599.2% —

Compare with peers

Head to head: IPSC vs XNCRIPSC vs KYMRIPSC vs SPRY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Century Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Century Therapeutics, Inc.